What is the share price of Biocon Ltd (BIOCON) today?
The share price of BIOCON as on 4th July 2025 is ₹380.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Biocon Ltd (BIOCON) share?
The past returns of Biocon Ltd (BIOCON) share are- Past 1 week: 6.41%
- Past 1 month: 10.70%
- Past 3 months: 15.94%
- Past 6 months: 6.13%
- Past 1 year: 5.19%
- Past 3 years: 22.08%
- Past 5 years: -5.42%
What are the peers or stocks similar to Biocon Ltd (BIOCON)?
The peers or stocks similar to Biocon Ltd (BIOCON) include:What is the dividend yield % of Biocon Ltd (BIOCON) share?
The current dividend yield of Biocon Ltd (BIOCON) is 0.30.What is the market cap of Biocon Ltd (BIOCON) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Biocon Ltd (BIOCON) is ₹50719.74 Cr as of 4th July 2025.What is the 52 week high and low of Biocon Ltd (BIOCON) share?
The 52-week high of Biocon Ltd (BIOCON) is ₹404.70 and the 52-week low is ₹291.What is the PE and PB ratio of Biocon Ltd (BIOCON) stock?
The P/E (price-to-earnings) ratio of Biocon Ltd (BIOCON) is 50.05. The P/B (price-to-book) ratio is 2.01.Which sector does Biocon Ltd (BIOCON) belong to?
Biocon Ltd (BIOCON) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Biocon Ltd (BIOCON) shares?
You can directly buy Biocon Ltd (BIOCON) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Biocon Ltd
BIOCON Share Price
BIOCON Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
BIOCON Performance & Key Metrics
BIOCON Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
50.05 | 2.01 | 0.30% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
37.15 | 6.59 | 0.82% |
from 15 analysts
Price Upside
Earnings Growth
Rev. Growth
BIOCON Company Profile
Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.
BIOCON Sentiment Analysis
BIOCON Sentiment Analysis
BIOCON Stock Summary · February 2025
In Q3 FY25, the company demonstrated resilience with a 10% year-on-year revenue growth, primarily driven by robust performance in the Biosimilars and Research Services segments, despite facing challenges in Generics. Management remains optimistic about future growth, bolstered by successful FDA audits and a strong product pipeline, particularly in the insulin market, where strategic expansions are underway. While operational pressures have led to a profit before tax loss, increased investments in R&D and new facilities are expected to enhance production capabilities and market positioning. The company is also strategically targeting emerging markets and preparing for significant government tenders, reflecting a proactive approach to capitalize on growth opportunities amidst competitive dynamics. Overall, the sentiment remains positive, with expectations for stable revenue ratios and improved margins in the near term.
BIOCON Stock Growth Drivers
BIOCON Stock Growth Drivers
7Regulatory and Operational Milestones
The company has achieved significant regulatory milestones, including successful outcomes from multiple FDA audits and
Financial Performance and Growth
The company reported a year-on-year operating revenue growth of 10% in the third quarter of
BIOCON Stock Challenges
BIOCON Stock Challenges
4Declining Revenue in Generics Business
The Generics business reported a year-on-year revenue decline of 2%, despite a 10% sequential growth
Increased Operating Expenses and R&D Investments
The company has faced higher operating expenses associated with new facilities and increased R&D investments,
BIOCON Forecast
BIOCON Forecasts
Price
Revenue
Earnings
BIOCON Share Price Forecast
BIOCON Share Price Forecast
All values in ₹
All values in ₹
BIOCON Company Revenue Forecast
BIOCON Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
BIOCON Stock EPS (Earnings Per Share) Forecast
BIOCON Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
BIOCON
BIOCON
Income
Balance Sheet
Cash Flow
BIOCON Income Statement
BIOCON Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 4,064.50 | 4,350.90 | 5,854.30 | 6,529.40 | 7,410.20 | 8,396.70 | 11,550.10 | 15,621.20 | 16,566.40 | 16,596.90 | ||||||||||
Raw Materials | 1,515.60 | 1,677.80 | 2,106.30 | 2,190.30 | 2,533.80 | 2,975.00 | 3,817.20 | 5,754.60 | 12,095.40 | 12,125.90 | ||||||||||
Power & Fuel Cost | 156.40 | 189.00 | 239.80 | 246.10 | 270.30 | 316.40 | 414.80 | 388.90 | ||||||||||||
Employee Cost | 747.00 | 931.10 | 1,165.30 | 1,458.80 | 1,741.00 | 1,880.10 | 2,181.00 | 2,664.10 | ||||||||||||
Selling & Administrative Expenses | 540.10 | 519.30 | 846.70 | 952.70 | 1,041.70 | 1,158.10 | 1,338.60 | 1,725.80 | ||||||||||||
Operating & Other expenses | -47.50 | -22.90 | -237.40 | -121.60 | -17.10 | 202.20 | 1,369.30 | 1,019.40 | ||||||||||||
EBITDA | 1,152.90 | 1,056.60 | 1,733.60 | 1,803.10 | 1,840.50 | 1,864.90 | 2,429.20 | 4,068.40 | 4,471.00 | 4,471.00 | ||||||||||
Depreciation/Amortization | 277.20 | 385.10 | 447.80 | 552.20 | 715.10 | 814.20 | 1,113.10 | 1,568.80 | 1,687.00 | 1,687.00 | ||||||||||
PBIT | 875.70 | 671.50 | 1,285.80 | 1,250.90 | 1,125.40 | 1,050.70 | 1,316.10 | 2,499.60 | 2,784.00 | 2,784.00 | ||||||||||
Interest & Other Items | 26.00 | 61.50 | 70.90 | 64.90 | 57.70 | 67.60 | 419.00 | 974.40 | 897.40 | 897.40 | ||||||||||
PBT | 849.70 | 610.00 | 1,214.90 | 1,186.00 | 1,067.70 | 983.10 | 897.10 | 1,525.20 | 1,886.60 | 1,886.60 | ||||||||||
Taxes & Other Items | 237.60 | 237.60 | 309.60 | 437.80 | 327.20 | 334.70 | 434.40 | 502.70 | 873.30 | 873.30 | ||||||||||
Net Income | 612.10 | 372.40 | 905.30 | 748.20 | 740.50 | 648.40 | 462.70 | 1,022.50 | 1,013.30 | 1,013.30 | ||||||||||
EPS | 5.10 | 3.10 | 7.54 | 6.23 | 6.17 | 5.40 | 3.85 | 8.52 | 8.46 | 8.44 | ||||||||||
DPS | 0.50 | 0.50 | 0.50 | 0.00 | 0.00 | 0.50 | 1.50 | 0.50 | 1.25 | 0.50 | ||||||||||
Payout ratio | 0.10 | 0.16 | 0.07 | 0.00 | 0.00 | 0.09 | 0.39 | 0.06 | 0.15 | 0.06 |
BIOCON Company Updates
Investor Presentation
BIOCON Stock Peers
BIOCON Past Performance & Peer Comparison
BIOCON Past Performance & Peer Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Biocon Ltd | 50.05 | 2.01 | 0.30% |
Onesource Specialty Pharma Ltd | -1,288.38 | 58.48 | — |
Sai Life Sciences Ltd | 97.17 | 16.95 | — |
Acutaas Chemicals Ltd | 57.88 | 13.45 | 0.12% |
BIOCON Stock Price Comparison
Compare BIOCON with any stock or ETFBIOCON Holdings
BIOCON Shareholdings
BIOCON Promoter Holdings Trend
BIOCON Promoter Holdings Trend
In last 6 months, promoter holding in the company has decreased by 6.18%
Pledged promoter holdings is insignificant
BIOCON Institutional Holdings Trend
BIOCON Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has increased by 1.34%
BIOCON Shareholding Pattern
BIOCON Shareholding Pattern
BIOCON Shareholding History
BIOCON Shareholding History
Mutual Funds Invested in BIOCON
Mutual Funds Invested in BIOCON
No mutual funds holding trends are available
Top 5 Mutual Funds holding Biocon Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2926% | Percentage of the fund’s portfolio invested in the stock 1.44% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/108 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8608% | Percentage of the fund’s portfolio invested in the stock 1.61% | Change in the portfolio weight of the stock over the last 3 months -0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/71 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6636% | Percentage of the fund’s portfolio invested in the stock 0.95% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 87/150 (0) |
Compare 3-month MF holding change on Screener
smallcases containing BIOCON stock
smallcases containing BIOCON stock
Looks like this stock is not in any smallcase yet.
BIOCON Events
BIOCON Events
BIOCON Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
BIOCON Dividend Trend
No dividend trend available
BIOCON Upcoming Dividends
BIOCON Upcoming Dividends
No upcoming dividends are available
BIOCON Past Dividends
BIOCON Past Dividends
Cash Dividend
Ex DateEx DateJul 4, 2025
Dividend/Share
₹0.50
Ex DateEx Date
Jul 4, 2025
Cash Dividend
Ex DateEx DateJul 5, 2024
Dividend/Share
₹0.50
Ex DateEx Date
Jul 5, 2024
Cash Dividend
Ex DateEx DateJul 7, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Jul 7, 2023
Cash Dividend
Ex DateEx DateJun 30, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2022
Cash Dividend
Ex DateEx DateJul 18, 2019
Dividend/Share
₹0.50
Ex DateEx Date
Jul 18, 2019
BIOCON Stock News & Opinions
BIOCON Stock News & Opinions
Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 372.5, up 1.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.26% on the day, quoting at 25518.4. The Sensex is at 83618.54, up 0.25%. Biocon Ltd has gained around 10.73% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 3.84% in last one month and is currently quoting at 22110.8, up 0.37% on the day. The volume in the stock stood at 26.19 lakh shares today, compared to the daily average of 65 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 374.3, up 1.3% on the day. Biocon Ltd is up 3.1% in last one year as compared to a 5% jump in NIFTY and a 9.9% jump in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live
The key equity benchmarks traded with moderate gains in morning trade. The Nifty traded above the 25,550 mark. Oil & gas shares jumped after declining in the past trading session. At 10:25 IST, the barometer index, the S&P BSE Sensex advanced 278.10 points or 0.33% to 83,687.79. The Nifty 50 index jumped 107.55 points or 0.43% to 25,561.55. In the broader market, the S&P BSE Mid-Cap index rose 0.43% and the S&P BSE Small-Cap index jumped 0.44%. The market breadth was positive. On the BSE 2,102 shares rose and 1,406 shares fell. A total of 209 shares were unchanged. New Listing: Shares of Indogulf Cropsciences were currently trading at Rs 109.50 at 10:27 IST on the BSE, representing a discount of 1.35% compared with the issue price of Rs 111. The scrip was listed at 111, matching the initial public offer (IPO) price. So far, the stock has hit a high of Rs 112.60 and a low of Rs 105.45. On the BSE, over 4.45 lakh shares of the company were traded in the counter so far. Buzzing Index: The Nifty Oil & Gas index advanced 0.70% to 11,921.55. The index declined 0.17% in the past trading session. Oil India (up 2.24%), Oil & Natural Gas Corpn (up 1.29%), GAIL (India) (up 1.18%), Gujarat State Petronet (up 1.06%), Gujarat Gas (up 0.92%), Bharat Petroleum Corporation (up 0.6%), Hindustan Petroleum Corporation (up 0.4%), Adani Total Gas (up 0.35%), Reliance Industries (up 0.31%) and Mahanagar Gas (up 0.24%) surged. Stocks in Spotlight: Biocon rose 0.42%. The company said that Biocon Biologics has received the European Commission (EC) marketing authorisation in the European Union (EU) for Vevzuo and Evfraxy biosimilars of Denosumab. Rail Vikas Nigam added 0.32%. The company said that its board has approved the appointment of Chandan Kumar Verma as chief financial officer (CFO) with effect from 2 July 2025.Powered by Capital Market - Live
Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). RANKL plays a crucial role in the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. By blocking RANKL, denosumab effectively inhibits the breakdown of bone, leading to increased bone mass and strength. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone. Evfraxy is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults. Clinical data showed that both Denosumab biosimilars have comparable quality, safety, and efficacy to the reference product. The marketing authorisation follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. Shreehas Tambe, CEO & managing director, Biocon Biologics, said: 'The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access to essential medicines, including to new therapeutic areas such as bone health. In the past 18 months, we have successfully secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion, and support for healthcare systems in the region.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.20% to currently trade at Rs 367.65 on the BSE. Powered by Capital Market - Live
This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor. It is prescribed for the treatment of several eye conditions. These include neovascular (wet) age-related macular degeneration (AMD). It also treats visual impairment caused by macular edema secondary to central retinal vein vein occlusion (CRVO). Visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) is another indication. Furthermore, it is used for diabetic macular edema (DME). It also treats myopic choroidal neovascularization (myopic CNV). The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, confirming that YESAFILI is highly similar with no clinically meaningful differences to EYLEA in terms of quality, safety, and efficacy. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: 'The approval of YESAFILI by Health Canada'the first biosimilar to EYLEA in Canada'is a proud moment for Biocon Biologics. We are excited that in July, Canada will be the first country where we will launch YESAFILI, making it our 10th biosimilar to be commercialized worldwide.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.96% to currently trade at Rs 353.90 on the BSE. Powered by Capital Market - Live
Biocon has successfully concluded a Qualified Institutions Placement (QIP), raising Rs 4,500 crore (approximately $523 million), marking its first equity fundraise since its IPO in 2004. The company issued 13.63 crore equity shares at Rs 330 per share. The QIP opened on June 16 and closed on June 19, attracting participation from a mix of domestic and foreign institutional investors. Major names in the final orderbook included SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Life, Nippon India Mutual Fund, Mirae Asset, Franklin Templeton, SBI General Insurance, Government Pension Fund Global, and BlackRock. The proceeds from the fundraise will be used for multiple strategic objectives, including purchasing optionally convertible debentures of Biocon Biologics from Goldman Sachs-managed funds, repaying certain borrowings, and meeting other financial and corporate needs. Following the issue, the combined stake of the promoter and promoter group stands at 54.45%, down from 60.64% as of March 2025. Siddharth Mittal, CEO and managing director, Biocon, said, The strong response to our QIP reflects deep investor conviction in Biocon's differentiated strategy and consistent execution. This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.86% to settle at Rs 351.60 on Friday, 20 June 2025. Powered by Capital Market - Live
CRISIL Ratings Limited has re-affirmed the Long Term rating of Biocon at CRISIL AA+/Stable and short term rating at CRISIL A1+.Powered by Capital Market - Live
Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 353.2, up 3.52% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 25209.65. The Sensex is at 82725.53, up 0.41%. Biocon Ltd has added around 7.63% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 4.53% in last one month and is currently quoting at 21948, up 0.51% on the day. The volume in the stock stood at 47.75 lakh shares today, compared to the daily average of 26.07 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 354.1, up 3.46% on the day. Biocon Ltd is up 4.22% in last one year as compared to a 8.09% gain in NIFTY and a 11.76% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live
Additionally, its wholly owned subsidiary, Biocon Pharma, has received CDSCO approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge). The said approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise. The approval was received from the CDSCO under the recently formulated 101 route that enables recognition of approvals granted by established and referenced serious regulatory authorities. Siddharth Mittal, chief executive officer and managing director, Biocon, said: 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India.' Biocon is an innovation-led global biopharmaceutical company focused on improving affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the U.S. and Europe The company's consolidated net profit surged 154.2% to Rs 344.50 crore on 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The counter shed 0.45% to end at Rs 334.05 on the BSE.Powered by Capital Market - Live
Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 343.8, up 1.3% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 25003.4. The Sensex is at 82230.01, down 0.12%. Biocon Ltd has added around 3.59% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 2.33% in last one month and is currently quoting at 21633.2, up 1% on the day. The volume in the stock stood at 7.5 lakh shares today, compared to the daily average of 36.71 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 344.85, up 1.2% on the day. Biocon Ltd is up 11.77% in last one year as compared to a 10.98% gain in NIFTY and a 13.77% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending March 25.Powered by Capital Market - Live
Rivaroxaban is a prescription medication used in the treatment of deep vein thrombosis and pulmonary embolism, to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation. The approval will further strengthen Biocon's portfolio of vertically integrated drug products,' the company said in a statement. Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. The company's consolidated net profit surged 154.24% to Rs 344.50 crore in Q4 FY25, compared with Rs 135.50 crore in Q4 FY24. Revenue from operations increased 12.76% YoY to Rs 4,417 crore during the period under review. The scrip rose 0.89% to currently trade at Rs 341.55 on the BSE. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 20.47%, vs industry avg of 21.18%
Over the last 5 years, market share decreased from 77.66% to 75.4%
Over the last 5 years, net income has grown at a yearly rate of 6.25%, vs industry avg of 20.36%